Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Bringing Medication-Free Options to Patients of Panic Disorders with Joe Perekupka and Dr. Robert Cuyler

PTSD affects 6.1-9.2% of the adult US population (Up To Date). Additionally, an estimated 4.7% of adults will experience a panic disorder in their lifetime (NIMH). Unfortunately, both disorders have high rates of becoming chronic and require difficult treatment programs and medications with adverse side effects.   On this episode of Highway to Health, David…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Highway to Health on MarketScale.

Share

PTSD affects 6.1-9.2% of the adult US population (Up To Date). Additionally, an estimated 4.7% of adults will experience a panic disorder in their lifetime (NIMH). Unfortunately, both disorders have high rates of becoming chronic and require difficult treatment programs and medications with adverse side effects.  

On this episode of Highway to Health, David Kemp talks to Joe Perekupka, CEO of Freespira, and Dr. Robert Cuyler, Chief Clinical Officer of Freespira, to discuss mental health and the drive behind Freespira’s drug-free PTSD treatments.   

Both guests apply habits to maintain mental wellness; they exercise their bodies to calm their minds. Dr. Cuyler distills it into “three ingredients, exercise, connection, and purpose. These are the three things that keep me grounded.” When treating trauma, depression, anxiety, panic disorders, and PTSD, a great deal of information is available on medication and exposure therapy. Unfortunately, each has massive downsides. 

Dr. Cuyler noted, “the challenge is using treatments that are hard to tolerate.” Even when executed well, exposure therapy is challenging for a patient to complete. The guests cite a recent study that found that about half of the people admitted to exposure therapy studies did not finish the treatment.  

The other common path—medication—has a broad spectrum of results. Drugs have varying degrees of effectiveness from person to person and take a long time to reach the desired effect. Medications also have a vast range of known and unknown side effects. “Once the patient stops these medications, there’s a huge relapse in their symptoms coming back again,” said Perekupka. These factors are critical for the founding of Freespira and its mission. Listen to the entire podcast now. 

Highway to Health

Part of this channel

Highway to Health

Healthcare innovation conversations for executives and technology buyers.

Visit the channel →

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments are facing challenges not with the AI models themselves, but with the data quality. Hospital CIOs report difficulties in scaling AI due to fragmented and poorly governed data. This highlights the need for better data management and governance in healthcare AI initiatives.

  • 01Data quality is a major obstacle in scaling healthcare AI deployments.
  • 02Hospital CIOs are encountering issues with fragmented data governance.
  • 03AI model performance is not the primary challenge in these initiatives.

Jul 11, 2026

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS England is investing £10bn in health technology, focusing on ambient voice technology and pathology digitization. This initiative aims to improve healthcare efficiency and patient outcomes. The commitment includes integrating advanced technologies into existing healthcare systems.

  • 01NHS England commits £10bn to health tech.
  • 02Focus areas include ambient voice technology and pathology digitization.
  • 03The initiative aims to enhance healthcare efficiency and patient care.

Jul 9, 2026

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada has introduced a national hospital data platform named Vital, which will initially connect real-time data from 160 hospitals across three provinces. The initiative is supported by $210 million in funding, with coordination provided by Unity Health Toronto. This platform aims to enhance healthcare data integration and accessibility across the country.

  • 01Vital platform will connect 160 hospitals across three Canadian provinces.
  • 02The initiative is supported by $210 million in funding.
  • 03Unity Health Toronto is coordinating the implementation of this platform.

Jul 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub